Wednesday, July 8, 2026

Drug profile · INN

maprotiline hydrochloride

maprotiline hydrochloride (MAPROTILINE HYDROCHLORIDE) is a norepinephrine transporter inhibitor. Associated with Beam Therapeutics. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 10
Pipeline programs 0
News articles 0
Drug details — maprotiline hydrochloride
US status
approved
Class
Route
ORAL
Patents
10
Programs
0
Data quality
0.89

Quick answer

maprotiline hydrochloride (MAPROTILINE HYDROCHLORIDE) is a norepinephrine transporter inhibitor. Associated with Beam Therapeutics. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN maprotiline hydrochloride
Brand MAPROTILINE HYDROCHLORIDE
Mechanism Norepinephrine transporter inhibitor
Target Sodium-dependent noradrenaline transporter
Route ORAL
Formulation TABLET

Mechanism of action

Norepinephrine transporter inhibitor

Primary target: Sodium-dependent noradrenaline transporter

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amitriptyline hydrochloride Norepinephrine transporter inhibitor
  2. atomoxetine hydrochloride Norepinephrine transporter inhibitor
  3. desipramine hydrochloride Norepinephrine transporter inhibitor
  4. desvenlafaxine fumarate Norepinephrine transporter inhibitor
  5. doxepin hydrochloride Norepinephrine transporter inhibitor
  6. duloxetine hydrochloride Norepinephrine transporter inhibitor
  1. US 12296053

    Nanomaterials comprising triols

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12268753

    Nanomaterials comprising a biodegradable feature

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12059477

    Nanomaterials

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12016908

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11752202

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11594345

    Method for producing Ac-225 from Ra-226

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11344609

    Compositions and methods for treating hemoglobinopathies

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11142760

    Compositions and methods for treating hemoglobinopathies

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10919019

    Apparatus for the synthesis of radiopharmaceutical products

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8287819

    Device for synthesis of radiopharmaceutical products

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is maprotiline hydrochloride?

maprotiline hydrochloride (MAPROTILINE HYDROCHLORIDE) is a norepinephrine transporter inhibitor. Associated with Beam Therapeutics. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for maprotiline hydrochloride?

MAPROTILINE HYDROCHLORIDE is a marketed brand name for maprotiline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of maprotiline hydrochloride?

maprotiline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.